Cargando…

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD

Donor lymphocyte infusion (DLI) is an option for relapsed hematologic malignancies or incomplete chimerism of non-malignant diseases following allogeneic hematopoietic cell transplantation (HCT). We analyzed the incidence of acute graft versus host disease (aGVHD) in patients treated with DLI. From...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Fiona, Warlick, Erica, Miller, Jeffrey S., MacMillan, Margaret, Verneris, Michael R., Cao, Qing, Weisdorf, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972636/ https://www.ncbi.nlm.nih.gov/pubmed/27064686 http://dx.doi.org/10.1038/bmt.2016.63

Ejemplares similares

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

The Potential Genes Mediate the Pathogenicity of Allogeneic CD4(+)T Cell in aGVHD Mouse Model
por: Yu, Zhengyu, et al.
Publicado: (2021)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice
por: Dorrance, Adrienne M., et al.
Publicado: (2022)

Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras
por: Wang, Hui, et al.
Publicado: (2012)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
por: Li, Xiaoqing, et al.
Publicado: (2020)

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies
por: Naserian, Sina, et al.
Publicado: (2020)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2
por: Zhao, Kai, et al.
Publicado: (2020)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation
por: Ash, S, et al.
Publicado: (2010)

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
por: Gao, Ya, et al.
Publicado: (2021)

Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders
por: Biagi, Elena, et al.
Publicado: (2019)

A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
por: Schäfer, Henning, et al.
Publicado: (2021)

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2023)

Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study
por: Han, Hongxing, et al.
Publicado: (2015)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering
por: Ye, Yishan, et al.
Publicado: (2022)

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model
por: Bouazzaoui, Abdellatif, et al.
Publicado: (2021)

Biomarkers for Allogeneic HCT Outcomes
por: Adom, Djamilatou, et al.
Publicado: (2020)

Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model
por: Jiang, Ming, et al.
Publicado: (2020)

Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity
por: Ding, Li, et al.
Publicado: (2020)

Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
por: Zhao, Yanna, et al.
Publicado: (2022)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020)

Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation
por: Lv, Meng, et al.
Publicado: (2013)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

HMGB1 Recruits TET2/AID/TDG to Induce DNA Demethylation in STAT3 Promoter in CD4(+) T Cells from aGVHD Patients
por: Xu, Xuejun, et al.
Publicado: (2020)

Healthy-like CD4(+) Regulatory and CD4(+) Conventional T-Cell Receptor Repertoires Predict Protection from GVHD Following Donor Lymphocyte Infusion
por: Schneider, Jessica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s1cfpi3kq301ld0v7gbv4tt5t6